Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).
Two pharmaceutical companies are eager to advance a different approach to treating lung cancer.